Dr. Brian Kotzin

He is a former member of the board of directors at Vera Therapeutics, Inc., Rigel Pharmaceuticals, Inc., and Kyverna Therapeutics, Inc. He served as Senior Vice President for Nektar Therapeutics, Inc., from April 2017 to June 2023, and has held various leadership positions at Nektar Therapeutics, Inc., including serving as Chief Medical Officer and Head of Clinical Development from January 2021 to September 2021 and again from May 2022 to June 2023. He currently is the interim Chief Medical Officer at Nektar Therapeutics, Inc. From 2004 to 2015, Dr. Kotzin was Vice President, Global and Clinical Development and Head, Inflammation Therapeutic Area at Amgen Inc., directing the global development efforts for product candidates in the inflammation area. During his employment at Amgen, he also served as Vice President of Translational Sciences and Head of Medical Sciences from 2006 to 2011.

Prior to entering the life sciences industry, Dr. Kotzin held several positions as a professor at the University of Colorado Health Sciences Center, where his research focused on immunopathogenesis of inflammatory diseases. He has also held leadership roles at several national organizations, including as a member of the American College of Rheumatology (ACR) Board of Directors, member and chairperson of the NIH Immunological Sciences Study Section, chairperson of the NIH Autoimmunity Centers of Excellence, and member of the board of directors for the Federation of Clinical Immunology Societies.